Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NT-I7 |
| Trade Name | |
| Synonyms | GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin |
| Drug Descriptions |
NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516). |
| DrugClasses | |
| CAS Registry Number | 2026634-47-7 |
| NCIT ID | C151927 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Anti-BCMA CAR-T cells + NT-I7 | Anti-BCMA CAR-T cells NT-I7 | 0 | 1 |
| Atezolizumab + NT-I7 | Atezolizumab NT-I7 | 0 | 2 |
| Dexamethasone + NT-I7 | Dexamethasone NT-I7 | 0 | 1 |
| Nivolumab + NT-I7 | NT-I7 Nivolumab | 0 | 1 |
| NT-I7 | NT-I7 | 0 | 4 |
| NT-I7 + Pembrolizumab | NT-I7 Pembrolizumab | 0 | 2 |
| NT-I7 + Radiotherapy + Temozolomide | NT-I7 Radiotherapy Temozolomide | 0 | 1 |